[Skip to Navigation]
Comment & Response
July 2014

Gabapentin Treatment for Alcohol Dependence—Reply

Author Affiliations
  • 1The Scripps Research Institute, Pearson Center for Alcoholism and Addiction, Research, La Jolla, California
  • 2Scripps Clinic and Scripps Green Hospital, La Jolla, California
JAMA Intern Med. 2014;174(7):1201-1202. doi:10.1001/jamainternmed.2014.1591

In Reply We are delighted to learn of Geisler and Ghosh’s interest in treating alcohol dependence and welcome the opportunity to address some of their misunderstandings about our report of a randomized clinical trial of gabapentin for the treatment of alcohol dependence.1 Contrary to their concern that ours was initially a 2-arm trial, our original protocol in fact specified a 3-arm dose-ranging design (gabapentin, 1800, 900, and 0 mg/d) and was reviewed as such by the National Institute on Alcohol Abuse and Alcoholism (NIAAA), the Scripps institutional review board, and the JAMA Internal Medicine (JAMA-IM) statistical reviewer (per JAMA-IM’s requirement that the original protocol be included with a clinical trial submission), and the clinicaltrials.gov link referenced by the authors specifies “dose ranging.”

Add or change institution